default author photo

Gyung-Min Park

University of Ulsan - Ulsan University Hospital

Ulsan

Korea, Republic of (South Korea)

  • University of Ulsan - Ulsan University Hospital

SCHOLARLY PAPERS

2

DOWNLOADS

124

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Sexual Difference and Relationship with Cardiovascular Risk Factors in Asymptomatic Coronary Disease

Number of pages: 23 Posted: 04 Jul 2022
Yong-Hoon Yoon, Gyung-Min Park, Jong-Young Lee, Jae-Hwan Lee, Jae-Hyung Roh, Tae oh Kim, Pil Hyung Lee, Jaewon Choe, Young-Hak Kim and Seung-Whan Lee
Chungnam National University - Chungnam National University Hospital, University of Ulsan - Ulsan University Hospital, Sungkyunkwan University - Kangbuk Samsung Hospital, Chungnam National University - Chungnam National University Hospital, Chungnam National University - Chungnam National University Hospital, University of Ulsan - Asan Medical Center, University of Ulsan - Asan Medical Center, University of Ulsan - Asan Medical Center, University of Ulsan - Asan Medical Center and University of Ulsan - Asan Medical Center
Downloads 84 (790,029)

Abstract:

Loading...

asymptomatic, coronary artery disease, coronary computed tomography angiography, risk factor, sex

2.

Empagliflozin Versus Dapagliflozin and Hepatocellular Carcinoma Risk in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes: A Nationwide Active-Comparator Cohort Study and Network Meta-Analysis

Number of pages: 25 Posted: 02 Jul 2026
Joonho Jeong, Jooyi Jung, Seungbong Han, Gyung-Min Park, Sangwoo Park, Mi HEE Jang and Neung Wha Park
University of Ulsan - Ulsan University Hospital, Korea University - College of Medicine, Korea University - College of Medicine, University of Ulsan - Ulsan University Hospital, University of Ulsan - Ulsan University Hospital, University of Ulsan - Ulsan University Hospital and University of Ulsan - Ulsan University Hospital
Downloads 40

Abstract:

Loading...

MASLD, Hepatocellular carcinoma, empagliflozin, dapagliflozin, SGLT2 inhibitor, diabetes mellitus